{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:01:41Z","timestamp":1787256101572,"version":"build-2736575974"},"reference-count":116,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.autrev.2024.103669","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T18:53:28Z","timestamp":1729277608000},"page":"103669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Towards personalized management of myasthenia gravis phenotypes: From the role of multi-omics to the emerging biomarkers and therapeutic targets"],"prefix":"10.1016","volume":"23","author":[{"given":"Carmela Rita","family":"Balistreri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Vinciguerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Monastero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103669_bb0005","article-title":"The omics technologies and liquid biopsies: advantages, limitations, applications","volume":"100039","author":"Magro","year":"2024","journal-title":"Med Omics"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev-pharmtox-010617-052446","article-title":"Precision medicine is not just genomics: the right dose for every patient","volume":"58","author":"Peck","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev-publhealth-040617-014158","article-title":"Precision medicine from a public health perspective","volume":"39","author":"Ramaswami","year":"2018","journal-title":"Annu Rev Public Health"},{"issue":"6","key":"10.1016\/j.autrev.2024.103669_bb0020","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jama.2015.17136","article-title":"Value of personalized medicine","volume":"315","author":"Snyderman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2024.103669_bb0025","first-page":"13","article-title":"Editorial: phenotypes of myasthenia gravis","author":"Li","year":"2022","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JND-140045","article-title":"The epidemiology of neuromuscular disorders: a comprehensive overview of the literature","volume":"2","author":"Deenen","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.autrev.2024.103669_bb0035","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0040","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.3390\/ijms24043730","article-title":"Clinical and pathologic features of congenital myasthenic syndromes caused by 35 genes-a comprehensive review","volume":"24","author":"Ohno","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2024.103669_bb0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1590\/0004-282x-anp-2022-s105","article-title":"Myasthenia gravis in clinical practice","volume":"80","author":"de Estephan","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.autrev.2024.103669_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109173","article-title":"Gut microbiota and metabolites in myasthenia gravis: early diagnostic biomarkers and therapeutic strategies","volume":"245","author":"Kang","year":"2022","journal-title":"Clin Immunol"},{"issue":"212","key":"10.1016\/j.autrev.2024.103669_bb0055","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0060","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1474-4422(16)00032-6","article-title":"Myasthenia gravis: subgroup classifications","volume":"15","author":"Li","year":"2016","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0065","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ene.15565","article-title":"Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal","volume":"30","author":"Meisel","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2024.103669_bb0070","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/B978-0-323-98818-6.00010-8","article-title":"Myasthenia gravis and congenital Myasthenic syndromes","volume":"195","author":"Gilhus","year":"2023","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.autrev.2024.103669_bb0075","author":"Bardhan"},{"key":"10.1016\/j.autrev.2024.103669_bb0080","article-title":"Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy","author":"Sacc\u00e0","year":"2023","journal-title":"Eur J Neurol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103669_bb0085","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.autrev.2024.103669_bb0090","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103669_bb0095","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1007\/s10072-023-06933-3","article-title":"Circulating MiRNAs drive personalized medicine based on subgroup classification in myasthenia gravis patients","volume":"44","author":"Huang","year":"2023","journal-title":"Neurol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2024.103669_bb0100","first-page":"2842","article-title":"Myasthenia gravis as a prognostic marker in patients with thymoma","volume":"10","author":"Cacho-D\u00edaz","year":"2018"},{"key":"10.1016\/j.autrev.2024.103669_bb0105","first-page":"11","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","author":"Fichtner","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103669_bb0110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/acn3.311","article-title":"Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis","volume":"3","author":"Lee","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103669_bb0115","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.autrev.2024.103669_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0125","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1172\/JCI81894","article-title":"Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases","volume":"126","author":"Dragin","year":"2016","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.autrev.2024.103669_bb0130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000945","article-title":"Immune skew of circulating follicular helper T cells associates with myasthenia gravis severity","volume":"8","author":"Ashida","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"issue":"3","key":"10.1016\/j.autrev.2024.103669_bb0135","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0140","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acn3.51312","article-title":"In-depth peripheral CD4+ T profile correlates with myasthenic crisis","volume":"8","author":"Huan","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103669_bb0145","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI85113","article-title":"Human regulatory B cells in health and disease: therapeutic potential","volume":"127","author":"Mauri","year":"2017","journal-title":"J Clin Investig"},{"issue":"6","key":"10.1016\/j.autrev.2024.103669_bb0150","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mus.25162","article-title":"B-cell\u2013activating factor is elevated in serum of patients with myasthenia gravis","volume":"54","author":"Kang","year":"2016","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.autrev.2024.103669_bb0155","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12883-024-03553-y","article-title":"Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa","volume":"24","author":"McCallion","year":"2024","journal-title":"BMC Neurol"},{"key":"10.1016\/j.autrev.2024.103669_bb0165","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231194821","article-title":"Objectivity, practicality, and significance of practice guidelines for the practicing neurologists: what we learnt from consensus criteria in CIDP, myasthenia gravis and inflammatory myopathies","volume":"16","author":"Dalakas","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"10.1016\/j.autrev.2024.103669_bb0170","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","article-title":"Italian recommendations for the diagnosis and treatment of myasthenia gravis","volume":"40","author":"Evoli","year":"2019","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2024.103669_bb0175","series-title":"Diagnostik und therapie der myasthenia gravis und des lambert-eaton syndroms","author":"Deutsche Gesellschaft fur Neurologie","year":"2017"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0180","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/nyas.13503","article-title":"The Association of British Neurologists\u2019 myasthenia gravis guidelines","volume":"1412","author":"Sussman","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0185","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ene.15565","article-title":"Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal","volume":"30","author":"Meisel","year":"2023","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103669_bb0190","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3233\/JND-230210","article-title":"Detection of autoantibodies against the acetylcholine receptor, evaluation of commercially available methodologies: fixed cell-based assay, radioimmunoprecipitation assay and enzyme-linked immunosorbent assay1","volume":"11","author":"Diogenes","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0195","first-page":"1070","article-title":"Myasthenia gravis: novel findings and perspectives on traditional to regenerative therapeutic interventions","volume":"14","author":"Huang","year":"2023","journal-title":"Aging Dis"},{"issue":"5","key":"10.1016\/j.autrev.2024.103669_bb0200","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.3390\/ijms25052641","article-title":"miRNA regulation of cell phenotype and parietal remodeling in atherosclerotic and non-atherosclerotic aortic aneurysms: differences and similarities","volume":"25","author":"Terriaca","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.autrev.2024.103669_bb0205","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.3390\/ijms23147548","article-title":"Promising strategies for preserving adult endothelium health and reversing its dysfunction: from liquid biopsy to new omics technologies and noninvasive circulating biomarkers","volume":"23","author":"Balistreri","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.autrev.2024.103669_bb0210","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.3390\/ijms20236015","article-title":"On the road to accurate biomarkers for cardiometabolic diseases by integrating precision and gender medicine approaches","volume":"20","author":"Scola","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2024.103669_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2021.111469","article-title":"Vascular ageing and the related complications in the brain: new insights on related mechanisms and their translational applications","volume":"196","author":"Balistreri","year":"2021","journal-title":"Mech Ageing Dev"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0220","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3390\/biomedicines12040721","article-title":"MiRNAs: from master regulators of gene expression to biomarkers involved in intercellular communication","volume":"12","author":"Levantini","year":"2024","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0225","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cmet.2019.07.011","article-title":"Extracellular MiRNAs: from biomarkers to mediators of physiology and disease","volume":"30","author":"Mori","year":"2019","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.autrev.2024.103669_bb0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2217\/epi-2018-0183","article-title":"Circulating MiRNAs as mediators in cell-to-cell communication","volume":"11","author":"B\u00e4r","year":"2019","journal-title":"Epigenomics"},{"issue":"5","key":"10.1016\/j.autrev.2024.103669_bb0235","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202302028R","article-title":"InflammamiRs in focus: delivery strategies and therapeutic approaches","volume":"38","author":"Akkaya-Ulum","year":"2024","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/j.autrev.2024.103669_bb0240","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3390\/ijms25031942","article-title":"Role of MicroRNAs in immune regulation with translational and clinical applications","volume":"25","author":"Ga\u00e1l","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2024.103669_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102438","article-title":"Clinical significance of MiRNAs in autoimmunity","volume":"109","author":"Zhang","year":"2020","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0250","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/acn3.24","article-title":"Circulating mi RNA S in myasthenia gravis: MiR-150-5p as a new potential biomarker","volume":"1","author":"Punga","year":"2013","journal-title":"Ann Clin Transl Neurol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2024.103669_bb0255","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","article-title":"Disease specific signature of circulating MiR-150-5p and MiR-21-5p in myasthenia gravis patients","volume":"356","author":"Punga","year":"2015","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1016\/j.autrev.2024.103669_bb0260","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103669_bb0265","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000450","article-title":"Thymectomy lowers the myasthenia gravis biomarker MiR-150-5p","volume":"5","author":"Molin","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.autrev.2024.103669_bb0270","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/mus.25493","article-title":"Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: a pilot study","volume":"56","author":"Westerberg","year":"2017","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.autrev.2024.103669_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091927","article-title":"Analysis of serum MiRNA profiles of myasthenia gravis patients","volume":"9","author":"Nogales-Gadea","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2024.103669_bb0280","article-title":"Role of toll-like receptors in neuroimmune diseases: therapeutic targets and problems","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103669_bb0285","first-page":"11","article-title":"MiR-146a in myasthenia gravis thymus bridges innate immunity with autoimmunity and is linked to therapeutic effects of corticosteroids","author":"Bortone","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103669_bb0290","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jneuroim.2018.05.003","article-title":"Circulating MicroRNA MiR-21-5p, MiR-150-5p and MiR-30e-5p correlate with clinical status in late onset myasthenia gravis","volume":"321","author":"Sabre","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0295","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2017","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2024.103669_bb0300","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jneuroim.2016.01.003","article-title":"Disease specific enrichment of circulating Let-7 family MicroRNA in MuSK+ myasthenia gravis","volume":"292","author":"Punga","year":"2016","journal-title":"J Neuroimmunol"},{"issue":"22","key":"10.1016\/j.autrev.2024.103669_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225573","article-title":"Mechanisms and functions of long non-coding RNAs at multiple regulatory levels","volume":"20","author":"Zhang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2024.103669_bb0310","series-title":"Identification of the regulatory role of LncRNA SNHG16 in myasthenia gravis by constructing a competing endogenous RNA network","first-page":"1123","volume":"19","author":"Wang","year":"2020"},{"key":"10.1016\/j.autrev.2024.103669_bb0315","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2017.08.008","article-title":"IFNA-AS1 regulates CD4 + T cell activation in myasthenia gravis though HLA-DRB1","volume":"183","author":"Luo","year":"2017","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0320","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1002\/jcb.27838","article-title":"The long noncoding RNA MALAT-1 functions as a competing endogenous RNA to regulate MSL2 expression by sponging MiR-338-3p in myasthenia gravis","volume":"120","author":"Kong","year":"2019","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.autrev.2024.103669_bb0325","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2016.09.005","article-title":"Expression profile of long noncoding RNAs and MRNAs in peripheral blood mononuclear cells from myasthenia gravis patients","volume":"299","author":"Zhang","year":"2016","journal-title":"J Neuroimmunol"},{"issue":"7","key":"10.1016\/j.autrev.2024.103669_bb0330","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/2211-5463.13656","article-title":"Epigenome-wide DNA methylation analysis of myasthenia gravis","volume":"13","author":"Lin","year":"2023","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.autrev.2024.103669_bb0335","first-page":"12","article-title":"Next-generation sequencing identifies extended HLA class I and II haplotypes associated with early-onset and late-onset myasthenia gravis in Italian, Norwegian, and Swedish populations","author":"Creary","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0340","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","article-title":"A genome-wide association study of myasthenia gravis","volume":"72","author":"Renton","year":"2015","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0345","first-page":"769","article-title":"Genome-wide association study of late-onset myasthenia gravis: confirmation of TNFRSF11A and identification of ZBTB10 and three distinct HLA associations","volume":"21","author":"Seldin","year":"2015"},{"issue":"3","key":"10.1016\/j.autrev.2024.103669_bb0350","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.26169","article-title":"Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease","volume":"90","author":"Handunnetthi","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103669_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2023.111793","article-title":"Sex differences in neuromuscular disorders","volume":"211","author":"Vinciguerra","year":"2023","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.autrev.2024.103669_bb0360","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.yjmcc.2019.02.014","article-title":"Polyamines and microbiota in bicuspid and tricuspid aortic valve aortopathy","volume":"129","author":"Forte","year":"2019","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0365","first-page":"392","article-title":"The role of human microbiota in myasthenia gravis: a narrative review","volume":"15","author":"Schir\u00f2","year":"2023"},{"issue":"7","key":"10.1016\/j.autrev.2024.103669_bb0370","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.3390\/ijms25073928","article-title":"Different levels of therapeutic strategies to recover the microbiome to prevent\/delay acute lymphoblastic leukemia (ALL) or arrest its progression in children","volume":"25","author":"Aronica","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2024.103669_bb0375","doi-asserted-by":"crossref","unstructured":"Schir\u00f2, G.; Colletti, T.; Piccoli, T.; Ragonese, P.; Salemi, G.; Balistreri, C. R.; D'amelio, M. Is the myasthenia gravis (MG) the result of age and sex\/gender? A narrative review for identifying genetic and epigenetic biomarkers for a differential mg management in old and young women. Preprints.org. doi:10.20944\/preprints202404.1538.v2.","DOI":"10.20944\/preprints202404.1538.v2"},{"issue":"8","key":"10.1016\/j.autrev.2024.103669_bb0380","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/nu14081647","article-title":"Exploring the gut microbiome in myasthenia gravis","volume":"14","author":"Thye","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.autrev.2024.103669_bb0385","series-title":"Differential gut microbiota and fecal metabolites related with the clinical subtypes of myasthenia gravis","volume":"11","author":"Tan","year":"2020"},{"key":"10.1016\/j.autrev.2024.103669_bb0390","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.csbj.2024.04.025","article-title":"Explainable machine learning model for identifying key gut microbes and metabolites biomarkers associated with myasthenia gravis","volume":"23","author":"Chang","year":"2024","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.autrev.2024.103669_bb0395","first-page":"14","article-title":"Machine learning strategy for identifying altered gut microbiomes for diagnostic screening in myasthenia gravis","author":"Chang","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.autrev.2024.103669_bb0400","article-title":"Gut bacterial microbiota in patients with myasthenia gravis: results from the MYBIOM study","volume":"14","author":"Totzeck","year":"2021"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0405","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32700-y","article-title":"Fecal microbiota profile in a group of myasthenia gravis patients","volume":"8","author":"Moris","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2024.103669_bb0410","first-page":"13","article-title":"Oral microbiota profile in a group of anti-AChR antibody\u2013positive myasthenia gravis patients","author":"Huang","year":"2022","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0415","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02034-0","article-title":"Metagenome-wide association study of gut microbiome revealed potential microbial marker set for diagnosis of pediatric myasthenia gravis","volume":"19","author":"Liu","year":"2021","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0420","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1515\/revneuro-2014-0021","article-title":"Targeting complement system to treat myasthenia gravis","volume":"25","author":"Huda","year":"2014","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.autrev.2024.103669_bb0425","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350816","article-title":"Complement-targeted therapeutics: are we there yet, or just getting started?","author":"Ricklin","year":"2024","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2024.103669_bb0430","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-024-07611-4","article-title":"Complement system activation: bridging physiology, pathophysiology, and therapy","author":"Azoulay","year":"2024","journal-title":"Intensive Care Med"},{"issue":"12","key":"10.1016\/j.autrev.2024.103669_bb0435","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0440","article-title":"Advances in understanding and managing myasthenia gravis: current trends and future directions","volume":"16","author":"Jaiswal","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2024.103669_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105231","article-title":"Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering","volume":"105","author":"Nelke","year":"2024","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.autrev.2024.103669_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287654","article-title":"Serum metabolomics of treatment response in myasthenia gravis","volume":"18","author":"Sikorski","year":"2023","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.autrev.2024.103669_bb0455","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11306-019-1571-9","article-title":"Beyond the antibodies: serum metabolomic profiling of myasthenia gravis","volume":"15","author":"Blackmore","year":"2019","journal-title":"Metabolomics"},{"key":"10.1016\/j.autrev.2024.103669_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119873","article-title":"Serum metabolomic profile of myasthenia gravis and potential values as biomarkers in disease monitoring","volume":"562","author":"Sha","year":"2024","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10.1016\/j.autrev.2024.103669_bb0465","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","article-title":"Emerging therapies for autoimmune myasthenia gravis: towards treatment without corticosteroids","volume":"30","author":"Tannemaat","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2024.103669_bb0470","doi-asserted-by":"crossref","DOI":"10.1007\/s40263-023-01059-8","article-title":"Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future","author":"Crisafulli","year":"2024","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0475","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.autrev.2024.103669_bb0480","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40259-020-00443-w","article-title":"Monoclonal antibody-based therapies for myasthenia gravis","volume":"34","author":"Alabbad","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.autrev.2024.103669_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115872","article-title":"Myasthenia gravis: molecular mechanisms and promising therapeutic strategies","volume":"218","author":"Chen","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.autrev.2024.103669_bb0490","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211065406","article-title":"Advances and challenges in the treatment of myasthenia gravis","volume":"14","author":"Schneider-Gold","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2024.103669_bb0495","author":"RemeGen Co., Ltd"},{"issue":"5","key":"10.1016\/j.autrev.2024.103669_bb0500","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s10787-021-00863-2","article-title":"Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases","volume":"29","author":"Khalesi","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.autrev.2024.103669_bb0505","author":"Roche"},{"key":"10.1016\/j.autrev.2024.103669_bb0510","first-page":"12","article-title":"Clinical efficacy and safety of Eculizumab for treating myasthenia gravis","author":"Xiao","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103669_bb0515","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/acn3.52051","article-title":"Real-world experience with eculizumab and switching to Ravulizumab for generalized myasthenia gravis","volume":"11","author":"Tokuyasu","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103669_bb0520","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","article-title":"Starting eculizumab as rescue therapy in refractory myasthenic crisis","volume":"44","author":"Vinciguerra","year":"2023","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2024.103669_bb0525","first-page":"14","article-title":"Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103669_bb0530","series-title":"Investigational RNAi therapeutic targeting C5 is efficacious in pre-clinical models of myasthenia gravis","first-page":"484","volume":"13","author":"Kusner","year":"2019"},{"key":"10.1016\/j.autrev.2024.103669_bb0535","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/ITT.S377056","article-title":"Novel immunotherapies for myasthenia gravis","volume":"12","author":"Nair","year":"2023","journal-title":"ImmunTargets Ther"},{"key":"10.1016\/j.autrev.2024.103669_bb0540","article-title":"Efgartigimod: first approval","author":"Heo","year":"2022","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.autrev.2024.103669_bb0545","first-page":"383","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0550","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00415-023-11970-1","article-title":"Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome","volume":"271","author":"Di Stefano","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2024.103669_bb0555","first-page":"11","article-title":"Novel treatments in myasthenia gravis","author":"Menon","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2024.103669_bb0560","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/ITT.S240874","article-title":"Bruton\u2019s tyrosine kinase inhibitors: a new therapeutic target for the treatment of SLE?","volume":"9","author":"Lorenzo-Vizcaya","year":"2020","journal-title":"ImmunTargets Ther"},{"key":"10.1016\/j.autrev.2024.103669_bb0565","article-title":"High-dose vitamin c therapy for symptomatic deficiency in a patient with myasthenia gravis and Crohn\u2019s disease","author":"Murphree","year":"2021","journal-title":"Nutr Clin Pract"},{"issue":"6","key":"10.1016\/j.autrev.2024.103669_bb0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269621","article-title":"Decreased salivary \u03b1-amylase activity responding to citric acid stimulation in myasthenia gravis with malnutrition","volume":"17","author":"Huang","year":"2022","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.autrev.2024.103669_bb0575","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mus.25552","article-title":"Exercise in myasthenia gravis: a feasibility study of aerobic and resistance training","volume":"56","author":"Rahbek","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.autrev.2024.103669_bb0580","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-2433-2","article-title":"The benefits and tolerance of exercise in myasthenia gravis (MGEX): study protocol for a randomised controlled trial","volume":"19","author":"Birnbaum","year":"2018","journal-title":"Trials"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T03:13:40Z","timestamp":1732677220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224001605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":116,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1568997224001605"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103669","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards personalized management of myasthenia gravis phenotypes: From the role of multi-omics to the emerging biomarkers and therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103669"}}